Literature DB >> 21400612

Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer.

Jennifer E Foreman1, Wen-Chi L Chang, Prajakta S Palkar, Bokai Zhu, Michael G Borland, Jennie L Williams, Lance R Kramer, Margie L Clapper, Frank J Gonzalez, Jeffrey M Peters.   

Abstract

This study critically examined the role of PPARβ/δ in colon cancer models. Expression of PPARβ/δ mRNA and protein was lower and expression of CYCLIN D1 protein higher in human colon adenocarcinomas compared to matched non-transformed tissue. Similar results were observed in colon tumors from Apc(+/Min-FCCC) mice compared to control tissue. Dietary administration of sulindac to Apc(+/Min-FCCC) mice had no influence on expression of PPARβ/δ in normal colon tissue or colon tumors. Cleaved poly (ADP-ribose) polymerase (PARP) was either increased or unchanged, while expression of 14-3-3ε was not influenced in human colon cancer cell lines cultured with the PPARβ/δ ligand GW0742 under conditions known to increase apoptosis. While DLD1 cells exhibited fewer early apoptotic cells after ligand activation of PPARβ/δ following treatment with hydrogen peroxide, this change was associated with an increase in late apoptotic/necrotic cells, but not an increase in viable cells. Stable over-expression of PPARβ/δ in human colon cancer cell lines enhanced ligand activation of PPARβ/δ and inhibition of clonogenicity in HT29 cells. These studies are the most quantitative to date to demonstrate that expression of PPARβ/δ is lower in human and Apc(+/Min-FCCC) mouse colon tumors than in corresponding normal tissue, consistent with the finding that increasing expression and activation of PPARβ/δ in human colon cancer cell lines inhibits clonogenicity. Because ligand-induced attenuation of early apoptosis can be associated with more late, apoptotic/necrotic cells, but not more viable cells, these studies illustrate why more comprehensive analysis of PPARβ/δ-dependent modulation of apoptosis is required in the future.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21400612      PMCID: PMC3482838          DOI: 10.1002/mc.20757

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  51 in total

1.  A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.

Authors:  W R Oliver; J L Shenk; M R Snaith; C S Russell; K D Plunket; N L Bodkin; M C Lewis; D A Winegar; M L Sznaidman; M H Lambert; H E Xu; D D Sternbach; S A Kliewer; B C Hansen; T M Willson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

Authors:  T C He; T A Chan; B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

3.  Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells.

Authors:  B H Park; B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

4.  Peroxisome proliferator activated receptor gamma expression is reduced in the colonic mucosa of acromegalic patients.

Authors:  Fausto Bogazzi; Federica Ultimieri; Francesco Raggi; Aurelio Costa; Maurizio Gasperi; Elisabetta Cecconi; Franco Mosca; Luigi Bartalena; Enio Martino
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

5.  Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding.

Authors:  P Escher; O Braissant; S Basu-Modak; L Michalik; W Wahli; B Desvergne
Journal:  Endocrinology       Date:  2001-10       Impact factor: 4.736

6.  The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients.

Authors:  Masahiro Yoshinaga; Kentaro Taki; Shinichi Somada; Yumiko Sakiyama; Norihiko Kubo; Toyoma Kaku; Satoru Tsuruta; Tetsuya Kusumoto; Hironori Sakai; Kazuhiko Nakamura; Ryoichi Takayanagi; Yoichi Muto
Journal:  Dig Dis Sci       Date:  2010-09-08       Impact factor: 3.199

7.  Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of acromegalic patients.

Authors:  Fausto Bogazzi; Federica Ultimieri; Francesco Raggi; Dania Russo; Paolo Viacava; Denise Cecchetti; Aurelio Costa; Sandra Brogioni; Chiara Cosci; Maurizio Gasperi; Luigi Bartalena; Enio Martino
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

8.  Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.

Authors:  Emi Osawa; Atsushi Nakajima; Koichiro Wada; Satoko Ishimine; Nobutaka Fujisawa; Toshihiko Kawamori; Nobuyuki Matsuhashi; Takashi Kadowaki; Masako Ochiai; Hisahiko Sekihara; Hitoshi Nakagama
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

Review 9.  Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors.

Authors:  Chih-Hao Lee; Peter Olson; Ronald M Evans
Journal:  Endocrinology       Date:  2003-06       Impact factor: 4.736

10.  The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells.

Authors:  Imad Shureiqi; Wei Jiang; Xiangsheng Zuo; Yuanqing Wu; Julie B Stimmel; Lisa M Leesnitzer; Jeffrey S Morris; Hui-Zhen Fan; Susan M Fischer; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

View more
  25 in total

Review 1.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Authors:  Jeffrey M Peters; Yatrik M Shah; Frank J Gonzalez
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

2.  Metastasis regulation by PPARD expression in cancer cells.

Authors:  Xiangsheng Zuo; Weiguo Xu; Min Xu; Rui Tian; Micheline J Moussalli; Fei Mao; Xiaofeng Zheng; Jing Wang; Jeffrey S Morris; Mihai Gagea; Cathy Eng; Scott Kopetz; Dipen M Maru; Asif Rashid; Russell Broaddus; Daoyan Wei; Mien-Chie Hung; Anil K Sood; Imad Shureiqi
Journal:  JCI Insight       Date:  2017-01-12

Review 3.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  PPARδ is a regulator of autophagy by its phosphorylation.

Authors:  Qian Gou; Yidan Jiang; Runyun Zhang; Ying Xu; Huihui Xu; Wenbo Zhang; Juanjuan Shi; Yongzhong Hou
Journal:  Oncogene       Date:  2020-05-21       Impact factor: 9.867

5.  Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ).

Authors:  Jeffrey M Peters; Jose L Morales; Frank J Gonzalez
Journal:  Drug Discov Today Dis Mech       Date:  2011-11-29

6.  PPARβ/δ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity.

Authors:  Maryam Goudarzi; Takayuki Koga; Combiz Khozoie; Tytus D Mak; Boo-Hyon Kang; Albert J Fornace; Jeffrey M Peters
Journal:  Toxicology       Date:  2013-07-10       Impact factor: 4.221

7.  Stable over-expression of PPARβ/δ and PPARγ to examine receptor signaling in human HaCaT keratinocytes.

Authors:  Michael G Borland; Combiz Khozoie; Prajakta P Albrecht; Bokai Zhu; Christina Lee; Tejas S Lahoti; Frank J Gonzalez; Jeffrey M Peters
Journal:  Cell Signal       Date:  2011-08-04       Impact factor: 4.315

8.  Inhibition of tumorigenesis by peroxisome proliferator-activated receptor (PPAR)-dependent cell cycle blocks in human skin carcinoma cells.

Authors:  Michael G Borland; Ellen M Kehres; Christina Lee; Ashley L Wagner; Brooke E Shannon; Prajakta P Albrecht; Bokai Zhu; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicology       Date:  2018-05-03       Impact factor: 4.221

9.  Activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits human breast cancer cell line tumorigenicity.

Authors:  Pei-Li Yao; Jose L Morales; Bokai Zhu; Boo-Hyon Kang; Frank J Gonzalez; Jeffrey M Peters
Journal:  Mol Cancer Ther       Date:  2014-01-24       Impact factor: 6.261

Review 10.  Targeting peroxisome proliferator-activated receptor-β/δ in colon cancer: how to aim?

Authors:  Min Xu; Xiangsheng Zuo; Imad Shureiqi
Journal:  Biochem Pharmacol       Date:  2012-10-04       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.